1. Home
  2. BELFB vs CRNX Comparison

BELFB vs CRNX Comparison

Compare BELFB & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc. Class B

BELFB

Bel Fuse Inc. Class B

HOLD

Current Price

$254.51

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.38

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFB
CRNX
Founded
1949
2008
Country
United States
United States
Employees
4964
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BELFB
CRNX
Price
$254.51
$36.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$174.25
$76.75
AVG Volume (30 Days)
250.0K
1.3M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
0.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$9.74
$720.10
Revenue Next Year
$6.34
$184.67
P/E Ratio
$42.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$70.87
$25.83
52 Week High
$308.27
$57.99

Technical Indicators

Market Signals
Indicator
BELFB
CRNX
Relative Strength Index (RSI) 46.66 44.09
Support Level $241.14 $33.19
Resistance Level $308.27 $37.23
Average True Range (ATR) 14.22 2.32
MACD -6.15 -0.44
Stochastic Oscillator 14.01 25.18

Price Performance

Historical Comparison
BELFB
CRNX

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: